Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Biomed Pharmacother ; 175: 116616, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38723516

ABSTRACT

Fluorescent probes are a powerful tool for imaging amyloid ß (Aß) plaques, the hallmark of Alzheimer's disease (AD). Herein, we report the synthesis and comprehensive characterization of 21 novel probes as well as their optical properties and binding affinities to Aß fibrils. One of these dyes, 1Ae, exhibited several improvements over FDDNP, an established biomarker for Aß- and Tau-aggregates. First, 1Ae had large Stokes shifts (138-213 nm) in various solvents, thereby reducing self-absorption. With a high quantum yield ratio (φ(dichloromethane/methanol) = 104), 1Ae also ensures minimal background emission in aqueous environments and high sensitivity. In addition, compound 1Ae exhibited low micromolar binding affinity to Aß fibrils in vitro (Kd = 1.603 µM), while increasing fluorescence emission (106-fold) compared to emission in buffer alone. Importantly, the selective binding of 1Ae to Aß1-42 fibrils was confirmed by an in cellulo assay, supported by ex vivo fluorescence microscopy of 1Ae on postmortem AD brain sections, allowing unequivocal identification of Aß plaques. The intermolecular interactions of fluorophores with Aß were elucidated by docking studies and molecular dynamics simulations. Density functional theory calculations revealed the unique photophysics of these rod-shaped fluorophores, with a twisted intramolecular charge transfer (TICT) excited state. These results provide valuable insights into the future application of such probes as potential diagnostic tools for AD in vitro and ex vivo such as determination of Aß1-42 in cerebrospinal fluid or blood.


Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Fluorescent Dyes , Alzheimer Disease/metabolism , Alzheimer Disease/diagnosis , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Humans , Fluorescent Dyes/chemistry , Peptide Fragments/metabolism , Peptide Fragments/cerebrospinal fluid , Brain/metabolism , Brain/pathology , Brain/diagnostic imaging , Molecular Docking Simulation , Molecular Dynamics Simulation , Plaque, Amyloid/metabolism , Plaque, Amyloid/pathology , Microscopy, Fluorescence/methods
2.
Molecules ; 25(21)2020 Nov 04.
Article in English | MEDLINE | ID: mdl-33158028

ABSTRACT

Hypercholesterolemia is a major cause of atherosclerosis development and premature cardiovascular disease (CVD). It leads to inflammation, which further accelerates atherosclerosis progression. Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by elevated serum LDL-c from birth, due to a disease-causing variant in one of the causative genes (LDLR, APOB, PCSK9). In polygenic hypercholesterolemia (PH), the disease-causing genetic variant is absent; it is likely the cumulative result of multiple single nucleotide polymorphisms in LDL metabolism-related genes and other factors, such as lifestyle and environment. In high risk groups, such as patients with FH, an effective primary prevention of CVD must begin in childhood. High-sensitivity C-reactive protein (hsCRP) and carotid intima media thickness (cIMT) are two potential minimally invasive correlates of inflammation and subclinical atherosclerosis progression. hsCRP and cIMT have been shown to be significantly increased in patients with FH and PH relative to healthy controls, with some studies yielding conflicting results. In this review, we aim to summarize current knowledge and recent findings regarding the applicability of hsCRP and cIMT as markers of low-grade inflammation and subclinical atherosclerosis, focusing especially on children and adolescents with hypercholesterolemia.


Subject(s)
Atherosclerosis , C-Reactive Protein/metabolism , Carotid Intima-Media Thickness , Hyperlipoproteinemia Type II , Apolipoprotein B-100/genetics , Apolipoprotein B-100/metabolism , Atherosclerosis/blood , Atherosclerosis/diagnosis , Atherosclerosis/genetics , C-Reactive Protein/genetics , Humans , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/diagnostic imaging , Hyperlipoproteinemia Type II/genetics , Inflammation/blood , Inflammation/diagnostic imaging , Inflammation/genetics , Proprotein Convertase 9/genetics , Proprotein Convertase 9/metabolism , Receptors, LDL/genetics , Receptors, LDL/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL